GENE ONLINE|News &
Opinion
Blog

2022-11-08| PolicySpecial

Supreme Court Rejects Juno, Welcomes Amgen Back to Patent Discussions

by Reed Slater
Share To
In an eventful week for pharma, the U.S. Supreme Court denied Juno Therapeutics’ request to reinstate a $1.2 billion award from Kite in a patent dispute. The Supreme Court also announced it would listen to Amgen’s bid to revive the patents for a cholesterol drug, Repatha, after a lawsuit with Sanofi and Regeneron. 

It's free! Log in now to read

LOG IN SUBSCRIBE NOW
LATEST
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
READ MORE
EVENT
2023-03-28
Reuters Events: Pharma USA 2023
Philadelphia, USA
2023-04-24
Cell & Gene Therapy Summit 2023
Brussels, Belgium
2023-04-28
Boston Chinese Investment Club 2023 Biotech Pitch Competition
Boston, USA
2023-11-16
3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE
Dubai, UAE
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2023 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top